美時 (1795.TW)

301.00 +14.00 (+4.88%) 收市：01:30PM CST

美時

No. 277 Song Ren Road
17th Floor Xin Yi District
Taipei 110
Taiwan
886 2 2700 5908
https://www.lotuspharm.com.tw

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Petar Antonov Vazharov	CEO & Director	34.72M	無	無
Mr. Zenon Zdunek	Vice President of Supply Chain & Operations	12.83M	無	無
Ms. Eeling Chan	Chief Financial Officer	5.19M	無	無
Ms. Gwen Hsieh	Chief Information Officer	無	無	無
Ms. Yu-Ying Yang	Associate Director of Co-Operate Communication	無	無	無
Boon Chong Tan	Deputy General Manager	無	無	無
Mr. Edin Buljubasic	Vice President	無	無	無
Yingming Yue	Vice President	無	無	無
Valerie Lau	Chief Commercial Officer-APAC	無	無	無
Mr. Manish Chawla	Vice President of Research and Development	無	無	無

截止 2021年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 TWD。

描述

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system diseases. The company also provides over-the-counter products. In addition, it engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. Further, the company offers management consultancy services; pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. The company has strategic partnership with NRX Pharmaceuticals. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan.

公司管治

截至 無 止，美時 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。